secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001664710-26-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics corporate presentation highlights Phase 2 data and cash runway into 2028
--------------------------------------------------------------------------------

- Phase 2 KER-050 in lower-risk MDS: 45% RBC transfusion independence at 24 weeks (ASH Dec 2025).
- Phase 2 KER-012 in PAH met primary endpoint: 35m improvement in 6-min walk distance at 24 weeks.
- Cash, equivalents and short-term investments of $367.4M as of Sep 30, 2025, funding operations into 2028.
- Upcoming milestones: KER-050 higher-risk MDS data mid-2026; KER-012 HFpEF trial start H1 2026; KER-065 Phase 1 data H1 2026.
- No new financing, leadership changes, or material agreements disclosed in the update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000003/0001664710-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000003/kros-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer